OOIR: Observatory of International Research

Papers

(The H4-Index of Liver International is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort	142
TIPS Superiority in Refractory Variceal Haemorrhage: Insights From the TIPSEMS ‐ VB	117
Response to Letter to the Editor: “Chronic Nanoplastic Exposure as a Novel Risk Amplifier for MASLD Progression”	96
Navigating portal hypertension: Unlocking safe passage to healthy pregnancy in EHPVO	95
Importance of gender differences in body composition for liver transplantation and the ‘Sarco‐Model’ study	93
Golexanolone improves fatigue, motor incoordination and gait and memory in rats with bile duct ligation	91
Cardiac Geometry in Cirrhosis: Translation to Public Health and Trial Design	90
Reply to “Probiotics for Hepatic Encephalopathy Prevention After TIPS : Still an Open Question”	84
Immunogenicity and safety of a third dose of anti‐SARS‐CoV‐2 BNT16b2 vaccine in liver transplant recipients	84
Benefits of Using cT1 for Risk Stratification in MASLD	74
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease	70
HBV cure—The light at the end of the tunnel?	69
Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK Biobank	63
Inside Front Cover	60
Is ageing a problematic hurdle to the efficacy of first‐line atezolizumab plus bevacizumab in hepatocellular carcinoma?	56
Different methodologies of protein induced by vitamin K absence or antagonist II in patients without hepatocellular carcinoma	52
Changing epidemiological features of hepatocellular carcinoma: Taiwan's position	52
Letter to the Editor regarding “Long‐term exposure to air pollution and incident non‐alcoholic fatty liver disease and cirrhosis”	52
Interpreting elevated liver blood test results through a genetic lens: A genome‐wide association study	51
Bringing evidence to the MAFLD‐MASLD debate	50
Association of Liver Disease and Chronic Pruritus: A Case–Control Study	48
Liver Disease Complicating Familial Mediterranean Fever: A Study on 66 Patients Out of 533 Adult From the JIR Cohort	47
Clarifying Treatment Pathway Differences and Exposure Bias in the CHIEF Cohort Study	47
On Evaluating GPT ‐4 for CHB Treatment Recommendations: Reproducibility, Vignette Design and Promp	44
The Relationship Between TNF‐α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders	43

Impact of socio‐economic environment on incidence of primary liver cancer in France between 2006 and 2016	42
Determinants of worse liver‐related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort	42
Assessing Treatment Heterogeneity in Predictive Models for HCC Retreatment Response	42
Reply to Reconsidering the Impacts of Steatotic Liver Disease on Adverse Pregnancy Outcomes	42
Evaluation of Pathogenic Variants Associated With Monogenic Disorders of Dyslipidemia in Patients With Well Characterised MASLD	41
Integrating PNPLA3 into clinical risk prediction	40
Epidemiology and Risk Determinants of Drug‐Induced Liver Injury: Current Knowledge and Future Research Needs	40
High disease burden and healthcare resource usage in patients with acute porphyria—A population‐based analysis	40
Increased platelet ratio in patients with decompensated cirrhosis indicates a higher risk of portal vein thrombosis	39
Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct‐acting antivirals	39
Hospitalisations With Cryoglobulin‐Related Diseases in Spain Over 25 Years	39
Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in Young Children With Chronic HCV Infection	38
Primary Biliary Cholangitis Increases Mortality Irrespective of Presence or Absence of Cirrhosis	37
Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC	37
Hepatocytic ballooning in non‐alcoholic steatohepatitis: Dilemmas and future directions	37